Cynata Therapeutics Ltd leaps another 25%: Have you missed the boat?

Despite the hype, Cynata Therapeutics Ltd (ASX:CYP) might not be the wonder stock its share price movements seem to indicate.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As sure as the sun rises everyday, share-market participants love to gamble.

I say 'participants', because owning shares doesn't automatically make you an 'investor'.

Oh no.

An investor buys a company (ideally with stable, growing revenues) for the long term, relying on management to improve the business and occasionally topping up his holdings with some extra cash or when prices decline.

Other market participants love to take a chance, chasing speculative wonder stocks up hill and down dale, all over the ASX.

Cynata Therapeutics Ltd (ASX: CYP) is the latest stock to excite the flock, following companies like Phytotech Medical Ltd (ASX: PYL), Freelancer Ltd (ASX: FLN), and many more.

Cynata soared this week after announcing that its patented 'Cymerus' stem cell production method was validated as suitable for production for therapeutic purposes.

While the low-cost and infinitely repeatable production process – which requires no costly and time consuming collection of candidates – has obvious appeal and should bring in strong revenues for the company, I have to sound several cautionary notes about Cynata's value as an investment.

First, the company earned $43,354 (yes, that's 43 thousand dollars, possibly less than your yearly wage) in revenue in the first half of 2015.

This may grow rapidly should demand for its stem cells ramp up, but the most recent reports have provided no indications for if and when this might happen.

Second, although Cynata has a low-cost, infinite source of stem cells, it has no application for them as its research has not yet reached human trials.

Cynata is currently preparing to conduct Phase 1 clinical trials, but this isn't very exciting considering how far away from regulatory approval Phase 1 trials actually are.

(You can find a full introduction to the four Phases of testing here)

Third, according to management, Cynata only has sufficient cash to see it through to the end of Phase 1 Clinical Trials.

Cynata's cash burn rate of ~$1.5 million every 6 months combined with the costs of clinical trials stacks up poorly against its cash balance of just over $6m.

So unless outside demand for stem cells picks up, Cynata is going to be looking for cash again soon.

Given the current high prices for shares, I think buyers at current prices are definitely at risk of some shock to their portfolio in coming months.

This is one company you're better off steering clear of for the time being.

For readers who are in the dark as to the process involved with treatment development and approval, I'm currently writing a series of articles designed to help you better recognise the risks of owning biotech stocks.  You can find part 1 here.

Motley Fool contributor Sean O'Neill doesn't own shares in any company mentioned.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »